Allspring Global Investments Holdings LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 43,368 shares of the medical technology company's stock after selling 1,093 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Stryker were worth $16,189,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $25,000. Capital A Wealth Management LLC purchased a new stake in Stryker during the 4th quarter worth $26,000. Rakuten Securities Inc. increased its stake in Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after buying an additional 68 shares during the period. City Holding Co. boosted its position in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after buying an additional 74 shares during the last quarter. Finally, VSM Wealth Advisory LLC purchased a new position in Stryker in the 4th quarter valued at about $36,000. 77.09% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. BTIG Research set a $403.00 target price on Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Roth Mkm lifted their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Evercore ISI cut their price objective on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.
View Our Latest Analysis on SYK
Insider Activity at Stryker
In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.90% of the company's stock.
Stryker Trading Up 0.0%
Shares of SYK stock traded up $0.19 during trading hours on Friday, reaching $392.00. 536,295 shares of the stock traded hands, compared to its average volume of 1,346,875. The business has a fifty day moving average price of $382.92 and a 200 day moving average price of $376.13. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $149.62 billion, a PE ratio of 52.97, a PEG ratio of 2.98 and a beta of 0.91.
Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.50 earnings per share. On average, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is 45.41%.
Stryker Profile
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
